Publications

2024 | Blood

Real-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicity.

Authors:

Locke FL, Siddiqi T, Jacobson CA, Ghobadi A, Ahmed S, Miklos DB, Perales MA, Munoz J, Fingrut WB, Pennisi M, Gauthier J, Shadman M, Gowda L, Mirza AS, Abid MB, Hong S, Majhail NS, Kharfan-Dabaja MA, Khurana A, Badar T, Lin Y, Bennani NN, Herr MM, Hu ZH, Wang HL, Baer A, Baro E, Miao H, Spooner C, Xu H, Pasquini MC

2024 | American Journal of Hematology

Benefit of axicabtagene ciloleucel versus chemoimmunotherapy in older patients and/or patients with poor ECOG performance status with relapsed or refractory large B-cell lymphoma after 2 or more lines of prior therapy.

Authors:

Lunning MA, Wang HL, Hu ZH, Locke FL, Siddiqi T, Jacobson CA, Ahmed S, Miklos DB, Lin Y, Hill BT, Ghobadi A, Neelapu SS, Westin J, Dieyi C, Field P, Miao H, Shahani SA, Patel A, Spooner C, Fu C, Muramoto D, Xu H, Pasquini MC

2024 | Transplantation and Cellular Therapy

Axicabtagene ciloleucel versus tisagenlecleucel for relapsed or refractory large B cell lymphoma: A systematic review and meta-analysis.

Authors:

Gagelmann N, Bishop M, Ayuk F, Bethge W, Glass B, Sureda A, Pasquini MC, Kröger N

2024 | Nat Med

Unanswered questions following reports of secondary malignancies after CAR-T cell therapy.

Authors:

Levine BL, Pasquini MC, Connolly JE, Porter DL, Gustafson MP, Boelens JJ, Horwitz EM, Grupp SA, Maus MV, Locke FL, Ciceri F, Ruggeri A, Snowden J, Heslop HE, Mackall CL, June CH, Sureda AM, Perales MA

2023 | Transplantation and Cellular Therapy

Paving the road for chimeric antigen receptor T cells: American Society for Transplantation and Cellular Therapy 80/20 Task Force consensus on challenges and solutions to improving efficiency of clinical center certification and maintenance of operations for commercially approved immune effector cell therapies.

Authors:

Nikiforow S, Frigault MJ, Frey NV, Gardner RA, Komanduri KV, Perales MA, Kebriaei P, Warkentin PI, Pasquini M, Aho JL, Levine BL, Heslop HE, Hlucky TL, Habucky K, Gharibo M, Jagasia M, Locke FL

2023 | Transplantation and Cellular Therapy

Multi-stakeholder qualitative interviews to inform measurement of patient reported outcomes after CAR-T.

Authors:

Akinola IM, Cusatis R, Pasquini MC, Shaw BE, Bollu V, Dalal A, Tesfaye M, Flynn KE

2022 | Transplantation and Cellular Therapy

Real-world evidence of axicabtagene ciloleucel for the treatment of large B cell lymphoma in the United States.

Authors:

Jacobson CA, Locke FL, Ma L, Asubonteng J, Hu ZH, Siddiqi T, Ahmed S, Ghobadi A, Miklos DB, Lin Y, Perales MA, Lunning MA, Herr MM, Hill BT, Ganguly S, Dong H, Nikiforow S, Hooper M, Kawashima J, Xu H, Pasquini MC

2022 | Cytotherapy

Need for aligning the definition and reporting of cytokine release syndrome (CRS) in immuno-oncology clinical trials.

Authors:

Stewart MD, McCall B, Pasquini M, Yang AS, Britten CD, Chuk M, De Claro RA, George B, Gormley N, Horowitz MM, Kowack E, McCoy C, Morrow PK, Okoye E, Ricafort R, Rossi J, Sharon E, Theoret M, Vegni F, Yu T, Allen J

2021 | Blood Advances

Allogeneic transplant and CAR-T therapy after autologous transplant failure in DLBCL: A noncomparative cohort analysis.

Authors:

Hamadani M, Gopal AK, Pasquini M, Kim S, Qiu X, Ahmed S, Lazaryan A, Bhatt VR, Daly A, Lulla P, Ciurea S, Gauthier J, Agrawal V, Grover NS, Lekakis L, Modi D, Dahi PB, Herr MM, Johnson PC, Hashmi H, Hematti P, Locke FL

2021 | Blood Advances

Blueprint for the discovery of biomarkers of toxicity and efficacy for CAR T cells and T-cell engagers.

Authors:

Paczesny S, Pasquini MC, Pavletic SZ, Agarwal A, Spellman S, Kean L, Bernatchez C, Gust J, Staedtke V, Perales M-A

2021 | Nature Reviews Clinical Oncology

Beyond the storm - subacute toxicities and late effects in children receiving CAR T cells.

Authors:

Shalabi H, Gust J, Taraseviciute A, Wolters PL, Leahy AB, Sandi C, Laetsch TW, Wiener L, Gardner RA, Nussenblatt V, Hill JA, Curran KJ, Olson TS, Annesley C, Wang H-W, Khan J, Pasquini MC, Duncan CN, Grupp SA, Pulsipher MA, Shah NN

2020 | Journal of Immunology

Cancer Moonshot Immuno-Oncology Translational Network (IOTN): Accelerating the clinical translation of basic discoveries for improving immunotherapy and immunoprevention of cancer.

Authors:

Annapragada A, Sikora A, Bollard C, Conejo-Garcia J, Cruz CR, Demehri S, Demetriou M, Demirdjian L, Fong L, Horowitz M, Hutson A, Kadash-Edmondson K, Kufe D, Lipkin S, Liu S, McCarthy C, Morgan M, Morris Z, Pan Y, Pasquini M, Schoenberger S, Van Allen E, Vilar E, Xing Y, Zha W, Odunsi A

2020 | Blood

Tocilizumab not associated with increased infection risk after CAR T-cell therapy: implications for COVID-19?

Authors:

Nikiforow S, Mansour M, Hu Z-H, Horowitz MM, Riches M, Hematti P, Turtle CJ, Zhang M-J, Perales M-A, Pasquini MC, Frigault MJ

2019 | Biology of Blood and Marrow Transplanta...

Autologous hematopoietic cell transplantation for treatment-refractory relapsing multiple sclerosis: Position statement from the American Society for Blood and Marrow Transplantation.

Authors:

Cohen JA, Baldassari LE, Atkins HL, Bowen JD, Bredeson C, Carpenter PA, Corboy JR, Freedman MS, Griffith LM, Lowsky R, Majhail NS, Muraro PA, Nash RA, Pasquini MC, Sarantopoulos S, Savani BN, Storek J, Sullivan KM, Georges GE

2018 | Biology of Blood and Marrow Transplanta...

ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells.

Authors:

Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, Maus MV, Park JH, Mead E, Pavletic S, Go WY, Eldjerou L, Gardner RA, Frey N, Curran KJ, Peggs K, Pasquini M, DiPersio JF, van den Brink MRM, Komanduri KV, Grupp SA, Neelapu SS

2018 | Biology of Blood and Marrow Transplanta...

Systemic sclerosis as an indication for autologous hematopoietic cell transplantation: Position statement from the American Society for Blood and Marrow Transplantation.

Authors:

Sullivan KM, Majhail NS, Bredeson C, Carpenter PA, Chatterjee S, Crofford LJ, Georges GE, Nash RA, Pasquini MC, Sarantopoulos S, Storek J, Savani B, St. Clair EW

2017 | JAMA Neurology

Long-term outcomes after autologous hematopoietic stem cell transplantation for multiple sclerosis.

Authors:

Muraro PA, Pasquini M, Atkins HL, Bowen JD, Farge D, Fassas A, Freedman MS, Georges GE, Gualandi F, Hamerschlak N, Havrdova E, Kimiskidis VK, Kozak T, Mancardi GL, Massacesi L, Moraes DA, Nash RA, Pavletic S, Ouyang J, Rovira M, Saiz A, Simoes B, Trnený M, Zhu L, Badoglio M, Zhong X, Sormani MP, Saccardi R

2012 | Biology of Blood and Marrow Transplanta...

Transplantation for autoimmune diseases in North and South America: A report of the Center for International Blood and Marrow Transplant Research.

Authors:

Pasquini MC, Voltarelli J, Atkins HL, Hamerschlak N, Zhong X, Ahn KW, Sullivan KM, Carrum G, Andrey J, Bredeson CN, Cairo M, Gale RP, Hahn T, Storek J, Horowitz MM, McSweeney PA, Griffith LM, Muraro PA, Pavletic SZ, Nash RA

2012 | Multiple Sclerosis Journal

A prospective, randomized, controlled trial of autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: A position paper.

Authors:

Saccardi R, Freedman MS, Sormani MP, Atkins H, Farge D, Griffith LM, Kraft G, Mancardi GL, Nash R, Pasquini M, Martin R, Muraro PA

2011 | Annals of the Rheumatic Diseases

Current state and future directions of autologous hematopoietic stem cell transplantation in systemic lupus erythematosus.

Authors:

Illei GG, Cervera R, Burt KR, Doria A, Hiepe F, Jayne D, Pavletic S, Martin T, Marmont A, Saccardi R, Voskuyl AE, Farge D